Serum peptide profiles in patients with carcinoid tumors

Kristine Calhoun, SuEllen Toth-Fejel, Julie Cheek, Rodney Pommier

    Research output: Contribution to journalArticle

    39 Citations (Scopus)

    Abstract

    Background: Patterns of elevated serum peptides may reveal additional markers and permit better classification of tumors based on (secondary) peptide secretion. Methods: Fasting peptide profiles were obtained from 31 carcinoid patients. vasoactive intestinal peptide (VIP), pancreatic polypeptide (PP), neurotensin, substance P, gastrin-releasing polypeptide (GRP), calcitonin, gastrin, and pancreastatin were measured. Peptide elevation patterns were correlated with disease sites, syndrome, and survival. Results: Elevations in patients were as follows: VIP 0%, PP 13%, neurotensin 10%, substance P 20%, GRP 3%, calcitonin 10%, and gastrin 3%. There were no consistent patterns of elevated peptides with regard to site or syndrome. Pancreastatin was elevated in 81% of profiles and was the only abnormal peptide in 57% of patients. Conclusion: Peptide profile results do not permit improved classification, predict syndrome development, or correlate with survival. In contrast, pancreastatin is elevated in most cases and may be utilized to monitor disease progression and evaluate response to therapy.

    Original languageEnglish (US)
    Pages (from-to)28-31
    Number of pages4
    JournalAmerican Journal of Surgery
    Volume186
    Issue number1
    DOIs
    StatePublished - Jul 1 2003

    Fingerprint

    Carcinoid Tumor
    Peptides
    Serum
    Gastrins
    Pancreatic Polypeptide
    Neurotensin
    Vasoactive Intestinal Peptide
    Calcitonin
    Substance P
    Survival
    Disease Progression
    Fasting

    Keywords

    • Carcinoid
    • Pancreastatin
    • Peptide profiles

    ASJC Scopus subject areas

    • Surgery

    Cite this

    Serum peptide profiles in patients with carcinoid tumors. / Calhoun, Kristine; Toth-Fejel, SuEllen; Cheek, Julie; Pommier, Rodney.

    In: American Journal of Surgery, Vol. 186, No. 1, 01.07.2003, p. 28-31.

    Research output: Contribution to journalArticle

    Calhoun, Kristine ; Toth-Fejel, SuEllen ; Cheek, Julie ; Pommier, Rodney. / Serum peptide profiles in patients with carcinoid tumors. In: American Journal of Surgery. 2003 ; Vol. 186, No. 1. pp. 28-31.
    @article{34cf37eecf53446893e9c669ab2d7045,
    title = "Serum peptide profiles in patients with carcinoid tumors",
    abstract = "Background: Patterns of elevated serum peptides may reveal additional markers and permit better classification of tumors based on (secondary) peptide secretion. Methods: Fasting peptide profiles were obtained from 31 carcinoid patients. vasoactive intestinal peptide (VIP), pancreatic polypeptide (PP), neurotensin, substance P, gastrin-releasing polypeptide (GRP), calcitonin, gastrin, and pancreastatin were measured. Peptide elevation patterns were correlated with disease sites, syndrome, and survival. Results: Elevations in patients were as follows: VIP 0{\%}, PP 13{\%}, neurotensin 10{\%}, substance P 20{\%}, GRP 3{\%}, calcitonin 10{\%}, and gastrin 3{\%}. There were no consistent patterns of elevated peptides with regard to site or syndrome. Pancreastatin was elevated in 81{\%} of profiles and was the only abnormal peptide in 57{\%} of patients. Conclusion: Peptide profile results do not permit improved classification, predict syndrome development, or correlate with survival. In contrast, pancreastatin is elevated in most cases and may be utilized to monitor disease progression and evaluate response to therapy.",
    keywords = "Carcinoid, Pancreastatin, Peptide profiles",
    author = "Kristine Calhoun and SuEllen Toth-Fejel and Julie Cheek and Rodney Pommier",
    year = "2003",
    month = "7",
    day = "1",
    doi = "10.1016/S0002-9610(03)00115-6",
    language = "English (US)",
    volume = "186",
    pages = "28--31",
    journal = "American Journal of Surgery",
    issn = "0002-9610",
    publisher = "Elsevier Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Serum peptide profiles in patients with carcinoid tumors

    AU - Calhoun, Kristine

    AU - Toth-Fejel, SuEllen

    AU - Cheek, Julie

    AU - Pommier, Rodney

    PY - 2003/7/1

    Y1 - 2003/7/1

    N2 - Background: Patterns of elevated serum peptides may reveal additional markers and permit better classification of tumors based on (secondary) peptide secretion. Methods: Fasting peptide profiles were obtained from 31 carcinoid patients. vasoactive intestinal peptide (VIP), pancreatic polypeptide (PP), neurotensin, substance P, gastrin-releasing polypeptide (GRP), calcitonin, gastrin, and pancreastatin were measured. Peptide elevation patterns were correlated with disease sites, syndrome, and survival. Results: Elevations in patients were as follows: VIP 0%, PP 13%, neurotensin 10%, substance P 20%, GRP 3%, calcitonin 10%, and gastrin 3%. There were no consistent patterns of elevated peptides with regard to site or syndrome. Pancreastatin was elevated in 81% of profiles and was the only abnormal peptide in 57% of patients. Conclusion: Peptide profile results do not permit improved classification, predict syndrome development, or correlate with survival. In contrast, pancreastatin is elevated in most cases and may be utilized to monitor disease progression and evaluate response to therapy.

    AB - Background: Patterns of elevated serum peptides may reveal additional markers and permit better classification of tumors based on (secondary) peptide secretion. Methods: Fasting peptide profiles were obtained from 31 carcinoid patients. vasoactive intestinal peptide (VIP), pancreatic polypeptide (PP), neurotensin, substance P, gastrin-releasing polypeptide (GRP), calcitonin, gastrin, and pancreastatin were measured. Peptide elevation patterns were correlated with disease sites, syndrome, and survival. Results: Elevations in patients were as follows: VIP 0%, PP 13%, neurotensin 10%, substance P 20%, GRP 3%, calcitonin 10%, and gastrin 3%. There were no consistent patterns of elevated peptides with regard to site or syndrome. Pancreastatin was elevated in 81% of profiles and was the only abnormal peptide in 57% of patients. Conclusion: Peptide profile results do not permit improved classification, predict syndrome development, or correlate with survival. In contrast, pancreastatin is elevated in most cases and may be utilized to monitor disease progression and evaluate response to therapy.

    KW - Carcinoid

    KW - Pancreastatin

    KW - Peptide profiles

    UR - http://www.scopus.com/inward/record.url?scp=0038798531&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0038798531&partnerID=8YFLogxK

    U2 - 10.1016/S0002-9610(03)00115-6

    DO - 10.1016/S0002-9610(03)00115-6

    M3 - Article

    C2 - 12842744

    AN - SCOPUS:0038798531

    VL - 186

    SP - 28

    EP - 31

    JO - American Journal of Surgery

    JF - American Journal of Surgery

    SN - 0002-9610

    IS - 1

    ER -